Susoctocog alfa

舒索凝血素α

Report date: 2024/03/27 10:54:18

Base Information

Drug NameSusoctocog alfa
Drug Alias NamePFVIII重组舒索凝血素α重组苏凝血素-8αRpfVIIIB-Domain deleted recombinant porcine factor VIII (OBI-1) +[17] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factor
Mechanisms of ActionCoagulation factor VIII replacementsCoagulation factor X stimulantsBlood coagulation pathway activation
TargetsCoagulation factor X
Therapy Area/IndicationsAcquired hemophiliaHemorrhageHemophilia A
Global Approved IndicationsAcquired hemophiliaHemorrhageHemophilia A
Approved Indications in ChinaHemophilia A
Original Approved Country/TerritoryUnited States
Original Approved Date2014/10/23
Country/TerritoryBulgariaCanadaUnited States +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBaxalta Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesTakeda (China) International Trading Co LtdBaxalta Innovations GmbhVetter Pharma-Fertigung Gmbh & Co Kg +[5] 
Inactive CompaniesTakeda (China) Holdings Co LtdBaxalta Incorporated
Active IndicationsAcquired hemophiliaHemorrhageHemophilia A
Inactive IndicationsN/A

Other Information

ATC CodeB02BD14
Related LinksDrugBankKEGG